1,723,870 research outputs found
HERStory Makers 2022: Neetu
No full textNeetu is a postdoctoral research associate at the Dublin Institute of Advanced Studies studying theoretical high-energy physics. She took part in HERStory Makers 2022.What is HERStory Makers?HERStory Makers is a social media competition for female-identifying early career researchers to share their research, their career journeys, and to inspire the next generation. Winners are selected by public vote. HERStory Makers is also part of EXPLORATHON, Scotland's contribution to European Researchers' Night.In 2022-23, EXPLORATHON was supported by the Engineering & Physical Sciences Research Council [grant number EP/X020894/1].Author contributions to contentNeetu conceived, planned, and recorded the video content. Kirsty Ross edited the video content to insert HERStory Maker credits, add subtitles, and maintain video length below Twitter/X limit of 2 mins and 20 secs, prior to scheduling the social media posts.</p
Supply chain dynamics in the automotive industry
No full textThesis (M.S.)--Massachusetts Institute of Technology, Technology and Policy Program, 1998.Includes bibliographical references (leaves 81-83).by Neetu S. Bhatia.M.S
Dr. Neetu Singh Tomar Ka Farrukhabad Janpad Men Jansampark Aur Vyaktion Ka Vivran
No full textDr. Neetu Singh Tomar Ka Farrukhabad Men Jansampark-Vyakti Vivran (Dated 07-02-2015 to Dated 05-02-2018
Dr. Neetu Singh Tomar Ka FARRUKHABAD Jile Men Braman Evam Jansampark Vivaran.
No full textDr. Neetu Singh Tomar Ka FARRUKHABAD Jile Men Braman Evam Jansampark Vivaran (Dated 07-02-2015 to Dated 05-02-2018
Development and Characterization of a Topical Ocular Delivery System for Hydrogen Sulfide for the Treatment of Glaucoma
No full textGlaucoma, an ocular neuropathy, is characterized by progressive degeneration of retinal neurons which can ultimately lead to blindness if left untreated. The current therapies for glaucoma provide only symptomatic management by reducing intraocular pressure (IOP), a prominent risk factor for glaucoma. Since glaucoma is reported even in normotensive patients, the ideal glaucoma medication should lower IOP and confer neuroprotection to retinal neurons. Hydrogen sulfide (H2S) has been reported to reduce IOP and elicit retinal neuroprotection in mammalian ocular tissues. However, its ocular delivery is a challenge due to its gaseous nature and narrow therapeutic index. Therefore, this study developed a novel lipid-based delivery system for Diallyl Trisulfide (DATS), a H2S donor, to provide sustained release of H2S up to 8-9 hours upon topical application on the cornea. A high-performance liquid chromatography (HPLC) method was developed and validated as per USP guidelines for the quantification of DATS. The solid lipid nanoparticles (SLNs) loaded with DATS were prepared by hot emulsification process and solvent evaporation method. DATS-SLNs characterized for particle size, zeta potential, drug loading, and encapsulation efficiency. DATS-SLNs were incorporated in PEG ointment bases, characterized for ease of corneal spreadability by rheometer, and release profile for DATS as well as H2S. A well resolved peak of DATS was detected at 2.8 mins run time. The method showed good linearity (R2 > 0.999) over the concentration range of 3.12-100 ug/mL. The interday and intraday standard deviations were 90%. Glyceryl monostearate was selected for preparing SLNs whose particle size, polydispersity index, zeta potential, drug loading, and encapsulation efficiency were 124 ± 2.67 nm, 0.189 ± 0.005, - 23.57 ± 3.22 mV, 2.16 ± 0.26%, and 79 ± 3.6 %, respectively. PEG ointment base incorporated with DATS-SLNs showed a sustained release of DATS up to 9 hours releasing 67.89 ± 2.04% of the initial loaded amount with corresponding H2S concentration of 112 ± 2.16 µM. Rheological data indicated the formulation exhibited a shear thinning flow and had a viscosity of 4,445 ± 123 Pa.s at 34℃ suggesting the ease in flowability of the delivery system developed. Future studies should focus on increasing drug load and evaluating its corneal permeability. Successful completion of this study will provide a better therapeutic strategy for glaucoma, a disease that affects 79.6 million patients worldwide.ProQuest Traditional Publishing Optio
Supplemental Material - Prevalence and determinants of chronic pain and persistent opioid use after surgery: A review of systematic reviews
No full textSupplemental Material for Prevalence and determinants of chronic pain and persistent opioid use after surgery: A review of systematic reviews by Neetu Bansal, Sheanne Ang, and Li-Chia Chen in British Journal of Pain</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
